Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Abstract While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of T2DM, particularly hypertension, may drive AF in the setting of T2DM. But direct m...

Full description

Bibliographic Details
Main Authors: Salva R. Yurista, Herman H. W. Silljé, Michiel Rienstra, Rudolf A. de Boer, B. Daan Westenbrink
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Cardiovascular Diabetology
Subjects:
Mitochondria
Diabetes
Atrial fibrillation
Sodium-glucose co-transporter-2 inhibitors
Online Access:https://doi.org/10.1186/s12933-019-0984-0

Similar Items

Similar Items